\n<\/p>\n
ImmunityBio, Inc. (NASDAQ:IBRX<\/a>) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2<\/b><\/a>. On March 24, BTIG maintained its Buy rating on ImmunityBio, Inc. (NASDAQ:IBRX) with a price target of $13 after a recent regulatory action by the Food and Drug Administration (FDA).<\/p>\n The FDA\u2019s Office of Prescription Drug Promotion sent a warning letter about promotional communications for ImmunityBio, Inc.\u2019s (NASDAQ:IBRX) ANKTIVA. The agency believes promotional messages were false or misleading and lacked adequate risk presentation. The company has 15 days to respond and explain what steps it will take.<\/p>\n BTIG sees this as mainly a compliance and promotion matter that can likely be resolved. Based on the precedent set by the Office of Prescription Drug Promotion, the research firm does not expect legal action or product withdrawal. BTIIG also pointed out that the recent drop in the stock price presents a potential buying opportunity ahead of BCG-na\u00efve bladder cancer data expected in the second half of 2026.<\/p>\n Earlier, on March 4, Piper Sandler increased its price target on ImmunityBio, Inc. (NASDAQ:IBRX) from $7 to $12 and kept an Overweight rating on the stock. The research firm forecasts US ANKTIVA net revenues to reach $195 million in 2026 after rising about 700% to $113 million in 2025.<\/p>\n ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company that is focused on developing and commercializing next-generation immunotherapies for cancer and infectious diseases.<\/p>\n While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/b><\/a>.<\/p>\n READ NEXT: <\/b>10 Best Car Stocks to Buy in 2026<\/b><\/a> and <\/b>10 Best AI Stocks to Buy for the Next 10 Years<\/b><\/a>.<\/b><\/p>\n Disclosure: None. <\/b> Follow Insider Monkey on Google News<\/b><\/a>.<\/b><\/p>\n<\/p><\/div>\n